Posterior reversible encephalopathy syndrome in a patient with Richter's syndrome on combination DA-R-EPOCH chemotherapy regimen: a case report
- PMID: 33840384
- PMCID: PMC8040238
- DOI: 10.1186/s13256-021-02780-y
Posterior reversible encephalopathy syndrome in a patient with Richter's syndrome on combination DA-R-EPOCH chemotherapy regimen: a case report
Abstract
Background: Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiologic entity characterized by headaches, altered mental status, seizures, visual loss, and a characteristic imaging pattern in brain magnetic resonance images. The exact etiology and pathogenesis of this condition are not yet fully elucidated.
Case presentation: A 72-year-old White man presented with 2 weeks of low-grade fever and chills, night sweats, fatigue, dysphagia, and new-onset rapidly increasing cervical lymphadenopathy. He had a history of chronic lymphocytic leukemia with transformation to diffuse large B-cell lymphoma for which he was started on dose-adjusted rituximab, etoposide, prednisone vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH). Shortly after treatment initiation, the patient developed severe airway obstruction due to cervical lymphadenopathy that required emergency intubation. A few days later, the cervical lymphadenopathy and the status of the airway improved, and sedation was consequently weaned off to plan for extubation. However, the patient did not recover consciousness and developed generalized refractory seizures. Brain magnetic resonance imaging revealed edema in the cortical gray and subcortical white matter of the bilateral occipital and inferior temporal lobes, consistent with PRES.
Conclusions: Posterior reversible encephalopathy syndrome refers to a neurological disorder and imaging entity characterized by subcortical vasogenic edema in patients who develop acute neurological signs and symptoms of a usually reversible nature in different settings, including chemotherapy. Despite its name, PRES is not always fully reversible, and permanent sequelae can persist in some patients. Clinicians should be aware of the possible association between chemotherapy and PRES to ensure early recognition and timely treatment.
Keywords: Chronic lymphocytic leukemia; DA-R-EPOCH; Diffuse large B-cell lymphoma; Posterior reversible encephalopathy syndrome; R-EPOCH; Richter syndrome.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures


Similar articles
-
Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature.Neurologist. 2016 Nov;21(6):112-117. doi: 10.1097/NRL.0000000000000105. Neurologist. 2016. PMID: 27801773 Free PMC article.
-
Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy.Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):225-230. doi: 10.1016/j.clml.2016.12.004. Epub 2017 Jan 10. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28169156
-
[Malignant lymphoma complicated with posterior reversible encephalopathy].Ugeskr Laeger. 2015 Sep 7;177(37):V03150236. Ugeskr Laeger. 2015. PMID: 26376238 Danish.
-
[Posterior reversible encephalopathy syndrome following paralytic ileus caused by vincristine in a patient with T cell lymphoblastic lymphoma].Rinsho Ketsueki. 2014 Feb;55(2):249-53. Rinsho Ketsueki. 2014. PMID: 24598194 Review. Japanese.
-
A rare case of diffuse large B-cell lymphoma-associated hemophagocytic lymphohistiocytosis.J Oncol Pharm Pract. 2021 Jan;27(1):250-252. doi: 10.1177/1078155220929750. Epub 2020 Jun 6. J Oncol Pharm Pract. 2021. PMID: 32507098
Cited by
-
A Pressing Emergency in Oncology: A Case Series of Patients With Posterior Reversible Encephalopathy Syndrome.Cureus. 2024 Dec 3;16(12):e75028. doi: 10.7759/cureus.75028. eCollection 2024 Dec. Cureus. 2024. PMID: 39749077 Free PMC article.
References
-
- Tadmor T, Shvidel L, Bairey O, et al. Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding Rituximab to chemotherapy, from the Israeli CLLStudy Group: Richter's transformation to diffuse large B-cell lymphoma. Am J Hematol. 2014;89(11):E218–E222. doi: 10.1002/ajh.23826. - DOI - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources